Insider Selling: William M. Haskel Sells 28,100 Shares of Cambrex Corp. Stock (CBM)
Cambrex Corp. (NYSE:CBM) SVP William M. Haskel unloaded 28,100 shares of the company’s stock in a transaction that occurred on Thursday, August 7th. The shares were sold at an average price of $22.50, for a total value of $632,250.00. The sale was disclosed in a filing with the SEC, which can be accessed through this link.
A number of research firms have recently commented on CBM. Analysts at First Analysis downgraded shares of Cambrex Corp. from an “overweight” rating to an “equal weight” rating in a research note on Friday. Analysts at Longbow Research raised their price target on shares of Cambrex Corp. to $27.00 in a research note on Tuesday. They now have a “buy” rating on the stock.
Cambrex Corp. (NYSE:CBM) traded down 1.72% during mid-day trading on Friday, hitting $21.77. The stock had a trading volume of 293,627 shares. Cambrex Corp. has a one year low of $12.56 and a one year high of $23.88. The stock has a 50-day moving average of $21.42 and a 200-day moving average of $20.33. The company has a market cap of $667.9 million and a price-to-earnings ratio of 20.78.
Cambrex Corp. (NYSE:CBM) last posted its quarterly earnings results on Friday, August 1st. The company reported $0.35 EPS for the quarter, beating the Thomson Reuters consensus estimate of $0.28 by $0.07. The company had revenue of $98.00 million for the quarter, compared to the consensus estimate of $92.70 million. During the same quarter in the prior year, the company posted $0.10 earnings per share. The company’s quarterly revenue was up 59.2% on a year-over-year basis. Analysts expect that Cambrex Corp. will post $1.11 EPS for the current fiscal year.
Cambrex Corporation (NYSE:CBM) is a life sciences company, which provides products and services, which accelerate and improve the development and commercialization of new and generic therapeutics.
Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.